Tri Locum Partners LP Bellus Health Inc. Transaction History

Tri Locum Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $8.23 Million - $11 Million	-919,747 Reduced 81.08%	214,661 $2.27 Million
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $806,162 - $1.25 Million	124,793 Added 12.36%	1,134,408 $10.5 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $187,271 - $269,119	33,682 Added 3.45%	1,009,615 $6.95 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $15,443 - $24,368	2,936 Added 0.3%	975,933 $7.86 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $1.61 Million - $3.97 Million	597,477 Added 159.11%	972,997 $5.97 Million
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.61 $14,669 - $21,745	-4,717 Reduced 1.24%	375,520 $1.17 Million
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $1.15 Million - $1.74 Million	380,237 New	380,237 $1.46 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.